NCT02470819

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

A Two Arm Pilot Study Utilizing Molecular Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer or Advanced Gynecological Malignancies

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Avera McKennan Hospital & University Health Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to examine the impact on progression-free survival of targeted therapy for breast cancer suggested by proteomic and genomic profiling.

Detailed description

To explore the impact of targeted therapy for breast cancer suggested by proteomic and genomic profiling using RPMA, targeted resequencing, IHC analysis, WGS, RNA-seq, and Exome sequencing on progression-free survival. When a molecular target cannot be identified, the patient will be treated with a therapy selected on an empirical basis by the investigator/treating physician at the individual site and will be followed for survival status. Only available, FDA-approved agents will be used.

Conditions

• Metastatic Breast Cancer
• Breast Tumor
• Advanced Gynecologic Cancer

Interventions

Type	Name	Description
GENETIC	Genetic profiling	genetic profiling

Timeline

• Start date: 2014-03-01
• Primary completion: 2018-10-30
• Completion: 2018-10-30
• First posted: 2015-06-12
• Last updated: 2018-11-07

Locations

1 site across 1 country: United States